OKYO
OKYO Pharma Ltd
$1.52
-1.94%
$51.4M
No data for this timeframe.
Vol
Market Cap$51.4M
Cap SizeMicro Cap
SEC Reports6
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001849296·Prev Close $1.55
Recent Activity
Jun 8, 2026
Insider
CERRONE GABRIELE M was granted 300,000 shares
Director @ $1.72 ($516.0K)
Jun 8, 2026
Insider
BRANCACCIO JOHN P was granted 6,500 shares
Director @ $1.85 ($12.0K)
Jun 8, 2026
Insider
Simon Willy Jules was granted 6,500 shares
Director @ $1.85 ($12.0K)
Jun 2, 2026
SEC
Bernard Denoyer filed a Form 3 initial statement of beneficial ownership with OKYO Pharma Ltd, disclosing options to acq
3 — Impact 2/10
Jun 1, 2026
SEC
Form 3 filing by director Simon Willy Jules discloses initial beneficial ownership in OKYO Pharma Ltd, including 6,435 s
3 — Impact 2/10
Jun 1, 2026
SEC
John P. Brancaccio filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his holdings in OKY
3 — Impact 2/10
Apr 7, 2026
earnings
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
<p>LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: <a href="h
Mar 19, 2026
Press
OKYO Pharma announced that Non-Executive Director John Brancaccio purchased 5,000 additional shares at $1.61, increasing
Impact 3/10
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$9.00 (Feb 2026)
Current $1.52
Low $7.00
Median $7.00
High $13.00
3 analysts
$7.00
$13.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 20, 2026 | Piper Sandler | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 | $-0.05 — $-0.05 | 1 | |
| Next Q | $-0.08 | $-0.08 — $-0.08 | 1 | |
| Current FY | $-0.10 | $-0.10 — $-0.10 | 1 | |
| Next FY | $-0.20 | $-0.20 — $-0.20 | -100% YoY | 1 |
Latest Reports
NEUTRAL
3
2/10
Bernard Denoyer filed a Form 3 initial statement of beneficial ownership with OKYO Pharma Ltd, disclosing options to acq
Jun 2, 2026
NEUTRAL
3
2/10
Form 3 filing by director Simon Willy Jules discloses initial beneficial ownership in OKYO Pharma Ltd, including 6,435 s
Jun 1, 2026
NEUTRAL
Press
3/10
OKYO Pharma announced that Non-Executive Director John Brancaccio purchased 5,000 additional shares at $1.61, increasing
Mar 19, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | CERRONE GABRIELE | A | $516.0K |
| Jun 8, 2026 | BRANCACCIO JOHN | A | $12.0K |
| Jun 8, 2026 | Simon Willy | A | $12.0K |
| Jun 8, 2026 | Shah Keeren | A | $74.0K |
| Jun 8, 2026 | Denoyer Bernard | A | $6.5K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
5 unique insiders with 5 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | CERRONE GABRIELE M | Director | AWARD | 300,000 | $1.72 | $516.0K |
| Jun 8, 2026 | BRANCACCIO JOHN P | Director | AWARD | 6,500 | $1.85 | $12.0K |
| Jun 8, 2026 | Simon Willy Jules | Director | AWARD | 6,500 | $1.85 | $12.0K |
| Jun 8, 2026 | Shah Keeren Rameshchandra | Chief Financial Officer | AWARD | 40,000 | $1.85 | $74.0K |
| Jun 8, 2026 | Denoyer Bernard | Director | AWARD | 3,500 | $1.85 | $6.5K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.3/10.
NEUTRAL
3
2/10
Bernard Denoyer filed a Form 3 initial statement of beneficial ownership with OKYO Pharma Ltd, discl
Jun 2, 2026
NEUTRAL
3
2/10
Form 3 filing by director Simon Willy Jules discloses initial beneficial ownership in OKYO Pharma Lt
Jun 1, 2026
NEUTRAL
3
2/10
John P. Brancaccio filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing
Jun 1, 2026
NEUTRAL
6-K
3/10
OKYO Pharma announced the appointment of Dr. Marta Sacchetti to its Scientific Advisory Board. Dr. S
May 19, 2026
NEUTRAL
PRESS-RELEASE
4/10
OKYO Pharma announced a Scientific Advisory Board meeting and upcoming data presentation at ASCRS 20
Apr 7, 2026
BULLISH
6-K
7/10
OKYO Pharma announced a Scientific Advisory Board meeting with ophthalmology experts and a data pres
Apr 7, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 89% buy across 9 analysts — 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$9.00 mean target (Feb 2026)
$7.00 Low
$13.00 High
| Metric | Value |
|---|---|
| Current Price | $1.52 |
| Target Low | $7.00 |
| Target Mean | $9.00 |
| Target Median | $7.00 |
| Target High | $13.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2025-12-31 |
$-0.05 | $-0.05 | $-0.05 | — | +0.0% | 0↑ 1↓ | $0.0B | — | 1 |
| Next Q 2026-03-31 |
$-0.08 | $-0.08 | $-0.08 | — | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-03-31 |
$-0.10 | $-0.10 | $-0.10 | — | — | — | $0.0B | 0.0% | 1 |
| Next FY 2027-03-31 |
$-0.20 | $-0.20 | $-0.20 | -100.0% | — | — | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.050 | |
| 30d ago | $-0.050 | |
| 60d ago | $-0.050 | |
| 90d ago | $-0.050 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 20, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 7, 2026
earnings
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
<p>LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=SZ8zGURU
Mar 19, 2026
m_and_a
OKYO Pharma Announces Director Acquires Shares
<p align="justify">LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: <a href="https://www.globenewswire.com/Track
Mar 19, 2026
m_and_a
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
<p align="justify">LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: <a href="https://www.globenewswire.com/Track